Earlier this month, the Czech media reported that a highly efficient
antiviral drug developed by Czech scientists has been shelved, reportedly
for fear it would compete with existing medicines manufactured by
pharmaceutical giants. The substance, known as MK-612, has been designed
at the Czech Academy of Sciences' Institute of Organic Chemistry and
Biochemistry - the same institution where the team of Professor Antonin
Holy have developed a number of antiviral drugs used to treat hepatitis or
HIV/AIDS.